Pharmaceutical Deal Trends (2010–2015) Research Report 1

Pharmaceutical Deal Trends (2010–2015) and InDepth Analysis of Recent Deal Activity
No of Pages – 77
Publishing Date - October 1, 2015
Browse detailed TOC, Tables, Figures, Charts in Pharmaceutical Deal Trends (2010–2015) and
In-Depth Analysis of Recent Deal Activity at- http://www.marketreportsworld.com/10074434
Pharmaceutical Deal Trends (2010–2015) and In-Depth Analysis of Recent Deal Activity
Summary
GBI Research’s latest report, "Pharmaceutical Deal Trends (2010–2015) and In-Depth Analysis of
Recent Deal Activity" discusses deal-making trends for a range of deal types, such as Mergers &
Acquisitions (M&A) and strategic alliances. It also examines preference by deal type, along with
disclosed deal values from 2010 to July 2015, covering start-ups, mid-level players, and big players.
Pharmaceutical companies use deal activity to enhance their research activities, regulatory approach,
geographic presence, commercialization, and sales. The increasing development of biologics,
especially in oncology, has given a significant boost to activity in recent years. Analysis suggests that
while the number of deals in 2015 (until July) was lower than the number of deals in 2014, deal value
in 2015 has already exceeded that of 2014. Looking at the entire period, although strategic deals were
more numerous, M&A deals had the highest deal value. Partnerships were the most preferred type of
deal activity, but saw the lowest deal value. North America led in terms of region, followed by
Europe and Asia-Pacific. Key deals covered in this report include the acquisition of Allergen by
Actavis, asset transactions between Novartis and GlaxoSmithKline, and the partnership between
Pfizer and Merck.
Scope
- Which challenges in the pharmaceutical industry are encouraging deal activity?
- How important is deal activity to the market?
Overview of deal activity from 2010 to 2015 - What are the trends for M&A and strategic deals, and what are the key differences between the
sectors?
- What was the trend for regional involvement in each year?
- How do variations in terms of therapy area preference affect deal activity?
Detailed analysis of recent deal activity - How do announced and completed deals vary?
- How do deals in 2014 and 2015 compare in terms of quarterly volume and value?
- Which regions or therapy areas have encouraged recent deal activity?
- Who are the key players?
Complete analysis of recent M&A deals - How do M&A deal types differ in terms of number and value?